✦ LIBER ✦

Outcomes of patients treated through the Canadian Fabry disease initiative

✍ Scribed by Sirrs, S.M.; Bichet, D.G.; Casey, R.; Clarke, J.T.R.; Lemoine, K.; Doucette, S.; West, M.L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline characteristics of patients enr

✍ S. Sirrs; J.T.R. Clarke; D.G. Bichet; R. Casey; K. Lemoine; G. Flowerdew; D.S. S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Benefit of enzyme replacement therapy in

✍ West, Michael; Bichet, Daniel; Casey, Robin; Clarke, Joe; Sirrs, Sandra; LeMoine 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Agalsidase Alfa and Agalsidase beta Have

✍ Michael West; Daniel Bichet; Robin Casey; Joe Clarke; Sandra Sirrs; Kaye LeMoine 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P18—Agalsidase Alfa and Agalsidase Beta

✍ M. West; D. Bichet; R. Casey; J. Clarke; S. Sirrs; K. LeMoine; C. Auray-Blais 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

P19—Influence of Anti-Agalsidase Antibod

✍ M. West; D. Bichet; R. Casey; J. Clarke; S. Sirrs; K. LeMoine; C. Auray-Blais 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

148. A randomized controlled trial

✍ Michael West; Kaye LeMoine; Daniel Bichet; Joe Clarke; Robin Casey; Sandra Sirrs 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 42 KB